Senior Oncology Medical Science Liaison (Sr. MSL) – Midwest at Bristol-Myers Squibb

United States

Bristol-Myers Squibb Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, Oncology, Medical DevicesIndustries

Requirements

Candidates must have a strong scientific background, preferably with an advanced degree (MD, PharmD, PhD) in a relevant scientific or clinical discipline. A minimum of 5 years of experience as a Medical Science Liaison (MSL) or in a similar role within the pharmaceutical or biotechnology industry is required. Demonstrated experience in oncology, particularly with radiopharmaceuticals or targeted therapies, is essential. Proven ability to establish and maintain relationships with Key Opinion Leaders (KOLs) and Healthcare Providers (HCPs) is necessary. Extensive travel within the assigned territory is expected.

Responsibilities

The Senior MSL will serve as the primary medical resource for the external healthcare community, facilitating peer-to-peer scientific exchange and translating complex science into patient care insights. Responsibilities include identifying medical needs related to disease and products within a defined geography, developing and maintaining relationships with KOLs and HCPs, and ensuring patients have access to clinical trial compounds and marketed products. The role involves gathering key medical insights from KOLs/HCPs, acting as a clinical and scientific advisor, and collaborating with internal teams (clinical development, clinical operations, medical affairs) to execute the therapeutic product development process. Additionally, the Senior MSL will contribute to launch and commercialization strategies, facilitate scientific exchange, and gather external insights to inform the company's understanding of the therapeutic landscape. This includes attending conferences, presenting scientific product information, and representing the company credibly within the oncology community.

Skills

Oncology
Medical Science Liaison
Biotechnology
Radioisotopes
Radiopharmaceuticals
Clinical Development
Scientific Communication
Therapeutic Areas
Solid Tumors
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Small Cell Lung Cancer (SCLC)
Breast Cancer

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters
1887Year Founded
$33,706.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Flexible Work Hours
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.
BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.
Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.
The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.
BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.
The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.
BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI